Arcutis Biotherapeutics, Inc.

NasdaqGS:ARQT 주식 리포트

시가총액: US$2.6b

Arcutis Biotherapeutics 배당 및 자사주 매입

배당 기준 점검 0/6

Arcutis Biotherapeutics 배당금을 지급한 기록이 없습니다.

핵심 정보

n/a

배당 수익률

-0.3%

자사주 매입 수익률

총 주주 수익률-0.3%
미래 배당 수익률0%
배당 성장률n/a
다음 배당 지급일n/a
배당락일n/a
주당 배당금n/a
배당 성향n/a

최근 배당 및 자사주 매입 업데이트

업데이트 없음

Recent updates

내러티브 업데이트 • May 18

ARQT: Q4 Execution And 2026 Revenue Guidance Will Support Further Upside

Analysts have nudged the blended price target on Arcutis Biotherapeutics slightly lower to about $34.63 from $34.75. This reflects modest tweaks to revenue growth, profit margin and P/E assumptions following recent Q4 driven model updates across the Street.
Seeking Alpha • May 15

Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound

Summary Arcutis Biotherapeutics (ARQT) is evolving into a specialized dermatology platform, leveraging ZORYVE's expanding indications, formulations, and prescriber base for compounding revenue growth. ARQT reported Q1 2026 net revenues of $105.4M (up 65% YoY), reaffirmed 2026 revenue guidance of $480–495M, and demonstrated a significant reduction in net loss with strong gross margins. ZORYVE's pediatric and primary care expansion, new product launches, and pipeline progress support ARQT’s strategy to capture a larger share of the chronic dermatology market. Despite premium valuation multiples, ARQT’s rapid revenue growth, positive operating cash flow, and commercial momentum justify a bullish outlook, contingent on continued execution and market penetration. Read the full article on Seeking Alpha
내러티브 업데이트 • Apr 21

ARQT: Raised 2026 Revenue Outlook And Q4 Performance Will Drive Further Upside

Analysts now cluster around a $35 price target for Arcutis Biotherapeutics, reflecting only a small shift of a few dollars from prior targets as recent Q4 results, updated revenue guidance, and ongoing commercialization progress for Zoryve are incorporated into refreshed models. Analyst Commentary Recent Street research converges around a $35 price target, with modest adjustments on either side as analysts refresh models following Q4 results, updated guidance, and ongoing Zoryve commercialization.
내러티브 업데이트 • Apr 07

ARQT: Higher 2026 Revenue Guidance And Q4 Execution Will Support Upside

Analysts now converge around a $35 price target for Arcutis Biotherapeutics, reflecting updated models following the Q4 report, revised revenue guidance, and ongoing assessments of Zoryve commercialization efforts. Analyst Commentary Recent Street research shows a tight cluster of targets around $35, with several firms updating their models after the Q4 report and revised guidance.
내러티브 업데이트 • Mar 24

ARQT: Strong Q4 Execution And Higher 2026 Guidance Will Support Confidence

Narrative Update The consensus analyst price target for Arcutis Biotherapeutics is now $35, reflecting modest model updates following the Q4 report, stronger than expected sales, higher revenue guidance, and a continued focus on maximizing the value of Zoryve. Analyst Commentary Recent research highlights a cluster of price targets around $35, with analysts updating their models after the Q4 report, revisions to revenue guidance, and continued emphasis on the Zoryve franchise.
내러티브 업데이트 • Mar 10

ARQT: Infant Data And Steroid Concerns Will Support Higher Confidence In Guidance

The analyst price target for Arcutis Biotherapeutics has been raised by $3, from $31.75 to $34.75, as analysts update their models following the Q4 report, higher management guidance, and ongoing confidence in Zoryve commercialization and revenue trajectory. Analyst Commentary Recent Street research on Arcutis Biotherapeutics clusters tightly around a US$35 price target, with most firms updating their models after the Q4 report and new management guidance.
내러티브 업데이트 • Feb 23

ARQT: Infant Data And Steroid Concerns Will Support Future Upside Potential

Analysts kept their price target for Arcutis Biotherapeutics steady at $31.75, citing only minor adjustments to assumptions for discount rate, revenue growth, profit margin, and future P/E to reflect updated views on the company’s risk profile and earnings potential. What's in the News Reported positive topline Phase 2 INTEGUMENT-INFANT data for ZORYVE cream 0.05% in 101 infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis, with low rates of adverse events, all mild to moderate, and no serious adverse events (Key Developments).
내러티브 업데이트 • Feb 08

ARQT: Infant Atopic Dermatitis Data Will Drive Future Upside Potential

Analysts have nudged their price target for Arcutis Biotherapeutics higher to US$31.75 from US$30.86, tying the change to updated fair value estimates, a slightly adjusted discount rate, and modest tweaks to long term revenue growth, profit margin, and future P/E assumptions. What's in the News Positive topline results from the INTEGUMENT-INFANT Phase 2 study of ZORYVE cream 0.05% in 101 infants with mild to moderate atopic dermatitis, with a low incidence of mild to moderate adverse events and 58% of participants reaching EASI-75 at Week 4 (company announcement).
내러티브 업데이트 • Jan 25

ARQT: Pediatric Dermatology Pipeline And 2026 Revenue Guide Will Support Upside

Analysts have trimmed their price targets for Arcutis Biotherapeutics by about $1 to roughly $31, citing updated assumptions around fair value, discount rate, profit margin, and future P/E that slightly adjust their overall outlook. What's in the News FDA accepted a supplemental New Drug Application for ZORYVE cream 0.3% to extend plaque psoriasis treatment to children aged 2 to 5 years, with a PDUFA target action date of June 29, 2026 (Company announcement).
내러티브 업데이트 • Jan 11

ARQT: Pediatric Dermatology Expansion And 2026 Revenue Outlook Will Support Upside

Analysts now see Arcutis Biotherapeutics' fair value at US$31.63 per share, with the latest price target grounded in updated assumptions around the discount rate, revenue growth, profit margins, and future P/E that remain broadly consistent with prior estimates. What's in the News The FDA accepted a supplemental New Drug Application for ZORYVE cream 0.3% to expand its plaque psoriasis indication to children aged 2 to 5 years, with a PDUFA target action date of June 29, 2026, supported by MUSE and long term safety studies in this age group (company announcement).
내러티브 업데이트 • Dec 21

ARQT: Pediatric Dermatology Expansion Will Support Stronger Long-Term Earnings Power

Analysts have modestly raised their price target on Arcutis Biotherapeutics by updating key valuation inputs, including a slightly higher discount rate and future earnings multiple. This results in a new implied fair value of 31.63 dollars per share that remains unchanged from prior estimates but is now underpinned by refined growth and margin assumptions.
분석 기사 • Dec 09

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Despite an already strong run, Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) shares have been powering on, with a gain...
내러티브 업데이트 • Dec 06

ARQT: Pediatric Approvals And Long-Term Data Will Support Gradual Portfolio Expansion

Analysts have nudged their price target on Arcutis Biotherapeutics slightly higher, from 31 dollars to approximately 31 dollars and 63 cents, citing modest improvements in long term revenue growth, profit margin expectations, and valuation multiples. What's in the News FDA accepted a supplemental new drug application to extend ZORYVE cream 0.3 percent plaque psoriasis treatment to children aged 2 to 5, with a PDUFA target action date of June 29, 2026 (Company press release).
내러티브 업데이트 • Nov 22

ARQT: Pediatric Launches And Recent Data Will Support Measured Progress Ahead

Analysts have maintained their price target for Arcutis Biotherapeutics at $31.00, citing stable growth estimates and consistent profit margin expectations. What's in the News The FDA accepted a supplemental New Drug Application (sNDA) for ZORYVE cream 0.3% to treat plaque psoriasis in children aged 2 to 5.
내러티브 업데이트 • Nov 06

ARQT: Expanded Pediatric Launch And Profit Margin Improvements Will Drive Sentiment Higher

Narrative Update on Arcutis Biotherapeutics Analysts have raised their price target for Arcutis Biotherapeutics from $23.38 to $31.00 per share, citing improved profit margin outlook and a slightly lower discount rate as key factors behind the adjustment. What's in the News The FDA approved ZORYVE (roflumilast) cream 0.05% for mild to moderate atopic dermatitis in children aged 2 to 5, providing a steroid-free topical option for young patients (FDA approval).
분석 기사 • Oct 31

Results: Arcutis Biotherapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit

Shareholders will be ecstatic, with their stake up 24% over the past week following Arcutis Biotherapeutics, Inc. 's...
내러티브 업데이트 • Oct 23

Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises

Arcutis Biotherapeutics saw its analyst price target raised by $5. Analysts cited strong product sales, robust prescription growth, and promising opportunities for future indication expansion as key drivers behind the upward revision.
새로운 내러티브 • Oct 20

Very Bullish

It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.
내러티브 업데이트 • Oct 09

Chronic Skin Trends Will Boost Non-Steroidal Treatment Adoption

Analysts have raised their price target for Arcutis Biotherapeutics from $22.75 to $23.38. The decision was based on stronger-than-expected product sales, ongoing commercial execution, and promising potential for expanded indications, all of which support mid- and long-term growth.
분석 기사 • Oct 02

Revenues Not Telling The Story For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) After Shares Rise 27%

Despite an already strong run, Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) shares have been powering on, with a gain...
내러티브 업데이트 • Sep 18

Chronic Skin Trends Will Boost Non-Steroidal Treatment Adoption

Upward analyst revisions for Arcutis Biotherapeutics reflect stronger-than-expected product sales, accelerating prescription growth, and optimism over Zoryve’s potential broader indications, lifting the consensus price target from $21.86 to $22.75. Analyst Commentary Bullish analysts highlighted Arcutis's stronger-than-expected total product sales and robust 19% quarter-over-quarter prescription growth, with stable gross-to-net (GTN) in the 50% range.
분석 기사 • Jul 15

Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • May 09

Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) defied analyst predictions to release its quarterly results, which were...
User avatar
새로운 내러티브 • Apr 26

FDA PDUFA Date And Payer Expansion Will Unlock Opportunity

Expanding ZORYVE's indications and payer coverage is expected to significantly boost revenue and market potential.
Seeking Alpha • Apr 19

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets

Summary Arcutis Biotherapeutics is rated a buy with a $19 price target, driven by strong Zoryve sales, a solid balance sheet, and strategic CFO transition. CFO David Topper is stepping down, replaced by Latha Vairavan, whose expertise aligns better with Arcutis's current commercial stage and financial goals. Zoryve's performance exceeds expectations, with significant revenue growth and expanded Medicaid coverage, bolstered by a robust sales force. Key upcoming milestones include regulatory events for Zoryve and clinical readouts for ARQ-255 and ARQ-234, supporting continued growth and valuation. Read the full article on Seeking Alpha
Seeking Alpha • Mar 12

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute

Summary Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth ahead via indication expansion for lead product Zoryve. After taking partial profits, the stock still accounts for 7.5% of my Core Biotech portfolio. Zoryve currently has ~3% market share in approved indications and management thinks 15% or above is within the realm of possibility. Balance sheet remains solid, revenue growth is steady, and the stock is starting to appeal to generalist growth investors. I continue to hold my remaining shares patiently as I anticipate continued execution by management and revenue acceleration in the 2025 to 2026 timeframe. Read the full article on Seeking Alpha
분석 기사 • Mar 09

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up

Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • Feb 26

Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations

Summary Arcutis Biotherapeutics is a strong buy due to ZORYVE's rapid sales growth and potential for positive earnings within 12 months. ZORYVE, a non-steroidal cream for psoriasis and dermatitis, saw Q4 sales of $69.4M, a 413% YoY increase, beating sales estimates by $10.8M. ZORYVE has maintained quarterly growth of >40% since Q1 2024. Remarkably only one additional quarter of such robust growth will bring sales to a pace needed to achieve profitability. I maintain a $21/share price target now within 12 months, driven by ZORYVE's growth and market disruption potential among traditional steroid treatments. Read the full article on Seeking Alpha
Seeking Alpha • Jan 23

Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period

Summary Arcutis Biotherapeutics, Inc. stock has surged 133% since January 2024 and over 60% since August due to impressive revenue growth, despite ongoing net losses and limited cash reserves. The company’s Zoryve topical cream products have shown strong prescription growth and improving margins, but the market cap of $1.6bn may be considered overvalued given current financials. Key developments in 2025 include potential FDA approvals, Medicaid and Medicare reimbursement expansions, and a co-promotion deal with Kowa Pharmaceuticals to boost market reach. Despite a strong product and potential for $500m annual sales, I downgrade ARQT shares to “Hold” due to competitive pressures, financial challenges, and expectations running a little too hot. Read the full article on Seeking Alpha
분석 기사 • Jan 02

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

지급의 안정성과 성장

배당 데이터 가져오는 중

안정적인 배당: 과거에 ARQT 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: ARQT 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

배당 수익률 vs 시장

Arcutis Biotherapeutics 배당 수익률 vs 시장
ARQT의 배당 수익률은 시장과 어떻게 비교되나요?
구분배당 수익률
회사 (ARQT)n/a
시장 하위 25% (US)1.4%
시장 상위 25% (US)4.3%
업계 평균 (Biotechs)2.4%
분석가 예측 (ARQT) (최대 3년)0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ARQT 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ARQT 의 배당 수익률을 평가할 수 없습니다.

주주 대상 이익 배당

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ARQT 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주 현금 배당

현금 흐름 범위: ARQT 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

높은 배당을 제공하는 우량 기업 찾기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/21 21:14
종가2026/05/21 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Arcutis Biotherapeutics, Inc.는 17명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Richard J. LawGoldman Sachs
null nullGuggenheim Securities, LLC
Seamus FernandezGuggenheim Securities, LLC